基于的有针对性的共价抑制剂
Fangyu Cao1, Ruo-Chen Guo1, Zeyu Zhang1
1Key Laboratory of Functional Polymer Materials, Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Institute of Polymer Chemistry, College of Chemistry, Nankai University, 94 Weijin Road, Tianjin 300071, China.
ACS applied materials & interfaces
|October 27, 2025
概括
基于的共价抑制剂提供有针对性的药物递送和提高选择性. 使用体自我组装的先进的输送系统通过克服诸如薄膜透性等局限性来提高其临床潜力.
科学领域:
- 药用化学 医学化学
- 药物运输 药物运输 药物运输
- 纳米技术纳米技术
背景情况:
- 协同抑制剂是先进的治疗药物,在克服耐药性方面具有更好的选择性和有效性.
- 由于它们的结合亲和力和生物相容性,类部分越来越多地被用作共价抑制剂中的配体.
- 临床转化中的挑战包括基于的共价抑制剂的薄膜透性和体内稳定性.
研究的目的:
- 审查近期对具有联体或通过组件传递的共价抑制剂的进展.
- 探索基于的共价抑制剂的设计策略,机制和应用.
- 讨论超分子组合在增强共价抑制剂递送和疗效方面的作用.
主要方法:
- 对基于的共价抑制剂及其输送系统的文献进行系统审查.
- 对结构-活性关系的分析和针对向共价抑制的设计策略.
- 评价自组装纳米结构作为药物输送平台.
主要成果:
- 酸连接体增强了对共价抑制剂的向性和选择性.
- 自组装的纳米结构显示有望控制释放和改善体内稳定性.
- 可控制的电友弹头对于减轻非目标效应至关重要.
结论:
- 基于的共价抑制剂及其输送系统代表了药物开发的前沿.
- 通过先进的交付策略克服当前的局限性是临床翻译的关键.
- 未来的研究应该专注于优化下一代共价药物的稳定性,透性和向释放.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Covalently Linked Protein Regulators
8.7K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
8.7K
Covalently Linked Protein Regulators
2.0K
2.0K
Dipeptidyl Peptidase 4 Inhibitors
581
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
581
Protein-protein Interfaces
14.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
14.4K
Drug-Receptor Bonds
4.2K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
4.2K


